Trastuzumab Deruxtecan 100mg/5mL vial lyophilized powder for concentrate for solution for infusion is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors
The facility is equipped with state-of-the-art technology to produce high-quality lyophilized (freeze-dried) products
The company has launched indigenously produced Dual Chamber Bags of global standards in India at a pocket-friendly price
Seasoned pharmaceutical R&D leader takes on an expanded leadership role to drive innovation and strengthen Hetero’s advanced formulation development capabilities
New Shoolagiri plant strengthens Maiva’s global CDMO capabilities with advanced isolator technology, flexible production lines, and expanded capacity for complex injectable therapies
Approval expands treatment options for patients with unresectable or metastatic HER2-positive breast cancer
Consolidated entity plans to strengthen specialty pharmaceutical offerings, expand manufacturing capacity, and accelerate global market penetration across emerging regions
The newly commissioned facility strengthens the ’company’s capabilities in the development and manufacturing of generic and complex sterile injectable products
Combined company targets Rs. 2,500–3,000 crore revenue by 2030; new sterile and OSD plants to begin operations by August 2026
New filling line approval supports delivery of integrated, end-to-end solutions across the entire biologics and bioconjugates value chain
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
